Close Menu

NEW YORK (GenomeWeb) – Editas Medicine is planning a public offering of 4 million shares of common stock, according to a document filed with the US Securities and Exchange Commission.

The Cambridge, Massachusetts-based firm said in a statement that it plans to use the proceeds to fund pre-clinical studies and clinical trials for CRISPR-based human therapies, specifically eye diseases, including Leber congenital amaurosis (LCA) 10.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.

New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.

The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.

In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.